Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$14.5 million.

  • Allogene Therapeutics' Net Cash Flow rose 8784.46% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year increase of 2545.12%. This contributed to the annual value of -$7.9 million for FY2024, which is 13734.88% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Net Cash Flow stood at -$14.5 million, which was up 8784.46% from $9.9 million recorded in Q2 2025.
  • Allogene Therapeutics' Net Cash Flow's 5-year high stood at $119.6 million during Q2 2024, with a 5-year trough of -$119.4 million in Q3 2024.
  • In the last 5 years, Allogene Therapeutics' Net Cash Flow had a median value of -$13.4 million in 2021 and averaged -$7.6 million.
  • The largest annual percentage gain for Allogene Therapeutics' Net Cash Flow in the last 5 years was 28888.7% (2023), contrasted with its biggest fall of 29435.53% (2023).
  • Allogene Therapeutics' Net Cash Flow (Quarter) stood at -$15.9 million in 2021, then grew by 21.5% to -$12.5 million in 2022, then soared by 211.69% to $13.9 million in 2023, then soared by 72.4% to $24.0 million in 2024, then crashed by 160.54% to -$14.5 million in 2025.
  • Its Net Cash Flow was -$14.5 million in Q3 2025, compared to $9.9 million in Q2 2025 and -$32.8 million in Q1 2025.